The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Left Ventricular Mass in Chronic Kidney Disease and ESRD
Abstract
Chronic kidney disease (CKD) and ESRD, treated with conventional hemo- or peritoneal dialysis are both associated with a high prevalence of an increase in left ventricular mass (left ventricular hypertrophy [LVH]), intermyocardial cell fibrosis, and capillary loss. Cardiac magnetic resonance imaging is the best way to detect and quantify these abnormalities, but M-Mode and 2-D echocardiography can also be used if one recognizes their pitfalls. The mechanisms underlying these abnormalities in CKD and ESRD are diverse but involve afterload (arterial pressure and compliance), preload (intravascular volume and anemia), and a wide variety of afterload/preload independent factors. The hemodynamic, metabolic, cellular, and molecular mediators of myocardial hypertrophy, fibrosis, apoptosis, and capillary degeneration are increasingly well understood. These abnormalities predispose to sudden cardiac death, most likely by promotion of electrical instability and re-entry arrhythmias and congestive heart failure. Current treatment modalities for CKD and ESRD, including thrice weekly conventional hemodialysis and peritoneal dialysis and metabolic and anemia management regimens, do not adequately prevent or correct these abnormalities. A new paradigm of therapy for CKD and ESRD that places prevention and reversal of LVH and cardiac fibrosis as a high priority is needed. This will require novel approaches to management and controlled interventional trials to provide evidence to fuel the transition from old to new treatment strategies. In the meantime, key management principles designed to ameliorate LVH and its complications should become a routine part of the care of the patients with CKD and ESRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
Eknoyan, G., Beck, G. J., Cheung, A. K., Daugirdas, J. T., Greene, T., Kusek, J. W., Allon, M., Bailey, J., Delmez, J. A., Depner, T. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021583 · Cited by 1,882
de Simone, G., Daniels, S. R., Devereux, R. B., Meyer, R. A., Roman, M. J., de Divitiis, O., & Alderman, M. H. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90385-z · Cited by 1,734
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barre, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 784
Hemodialysis-Induced Cardiac Injury: Determinants and Associated Outcomes
Burton, J. O., Jefferies, H. J., Selby, N. M., & McIntyre, C. W. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03900808 · Cited by 686
Culleton, B. F., Walsh, M., Klarenbach, S. W., Mortis, G., Scott-Douglas, N., Quinn, R. R., Tonelli, M., Donnelly, S., Friedrich, M. G., Kumar, A., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1291 · Cited by 683
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy
Cice, G., Ferrara, L., D’Andrea, A., D’Isa, S., Di Benedetto, A., Cittadini, A., Russo, P. E., Golino, P., & Calabrò, R. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00241-9 · Cited by 537
Cited by
Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021) · Circulation · doi:10.1161/circulationaha.120.050686 · Cited by 1,904
Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality
Flythe, J. E., Kimmel, S. E., & Brunelli, S. M. (2011) · Kidney International · doi:10.1038/ki.2010.383 · Cited by 501
Xie, J., Yoon, J., An, S.-W., Kuro-o, M., & Huang, C.-L. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040325 · Cited by 263
Metadata
- Authors
- Glassock, R. J., Pecoits-Filho, R., & Barberato, S. H.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-12
- Volume
- 4
- Issue
- Supplement_1
- Pages
- S79-S91
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2151284198
- Cited by
- 352
- References
- 74
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Left Ventricular Mass in Chronic Kidney Disease and ESRD. https://app.cochat.ai/papers/10.2215/cjn.04860709
- The paper
- Glassock, R. J., Pecoits-Filho, R., & Barberato, S. H. (2009). Left Ventricular Mass in Chronic Kidney Disease and ESRD. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.04860709
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.